• First Published: 19 October 2022

• First Published: 19 October 2022

• First Published: 19 October 2022

• Pages: 1231-1232
• First Published: 19 October 2022

• Pages: 1233-1236
• First Published: 03 May 2022

• Pages: 1237-1239
• First Published: 06 April 2022

• Pages: 1240-1242
• First Published: 16 April 2022

• Pages: 1243-1245
• First Published: 03 May 2022

• Pages: 1246-1247
• First Published: 05 April 2022

IMMUNE-MEDIATED DISEASES, DILI, AND BILIARY TRACT DISEASE

no

Identification of the chloride channel, leucine-rich repeat-containing protein 8, subfamily a (LRRC8A), in mouse cholangiocytes

Nikolay Shcheynikov,  Kristy Boggs,  Anthony Green,  Andrew P. Feranchak, 

• Pages: 1248-1258
• First Published: 21 April 2022

• Abstract
• Full text
• PDF
• References

Open Access

oa

Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia

Marta Alonso-Peña,  Ricardo Espinosa-Escudero,  Elisa Herraez,  Oscar Briz,  Maria Luisa Cagigal,  Jesus M. Gonzalez-Santiago,  Aida Ortega-Alonso,  Conrado Fernandez-Rodriguez,  Luis Bujanda,  Marta Calvo Sanchez,  Delia D´Avola,  Maria-Carlota Londoño,  Moises Diago,  Jose C. Fernandez-Checa,  Carmen Garcia-Ruiz,  Raul J. Andrade,  Frank Lammert,  Jesus Prieto,  Javier Crespo,  Javier Juamperez,  Alvaro Diaz-Gonzalez,  Maria J. Monte,  Jose J. G. Marin, 

• Pages: 1259-1274
• First Published: 08 April 2022

• Abstract
• Full text
• PDF
• References

LIVER CANCER

no

A developmentally prometastatic niche to hepatoblastoma in neonatal liver mediated by the Cxcl1/Cxcr2 axis

Li Fan,  Qingfei Pan,  Wentao Yang,  Selene C. Koo,  Cheng Tian,  Liyuan Li,  Meifen Lu,  Anthony Brown,  Bensheng Ju,  John Easton,  Sarangarajan Ranganathan,  Soona Shin,  Alexander Bondoc,  Jun J. Yang,  Jiyang Yu,  Liqin Zhu, 

• Pages: 1275-1290
• First Published: 18 February 2022

• Abstract
• Full text
• PDF
• References

no

Dynamic risk profiling of HCC recurrence after curative intent liver resection

Tommy Ivanics,  Carla Fiorella Murillo Perez,  Marco P. A. W. Claasen,  Madhukar S. Patel,  Gabriela Morgenshtern,  Lauren Erdman,  Chaya Shwaartz,  Luckshi Rajendran,  Grainne M. O’Kane,  Bettina E. Hansen,  Sean P Cleary,  Gonzalo Sapisochin, 

• Pages: 1291-1301
• First Published: 18 February 2022

• Abstract
• Full text
• PDF
• References

Open Access

oa

Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression

Tingjie Wang,  Chuanrui Xu,  Zhijing Zhang,  Hua Wu,  Xiujuan Li,  Yu Zhang,  Nan Deng,  Ningxin Dang,  Guangbo Tang,  Xiaofei Yang,  Bingyin Shi,  Zihang Li,  Lei Li,  Kai Ye, 

• Pages: 1302-1317
• First Published: 27 March 2022

• Abstract
• Full text
• PDF
• References

no

Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria

Jordi Rimola,  Víctor Sapena,  Giuseppe Brancatelli,  Anna Darnell,  Laura Forzenigo,  Aline Mähringer-Kunz,  Anita Paisant,  Matteo Renzulli,  Wolfgang Schima,  Sylvain Terraz,  Carlos Valls,  Mathilde Wagner,  Carmen Ayuso,  Valerie Vilgrain,  Maria Reig,  Maxime Ronot, 

• Pages: 1318-1328
• First Published: 29 March 2022

• •The reliability of extracellular contrast and gadolinium in small liver lesions using LI-RADS and EASL criteria have been investigated.
• •The agreement for definite HCC was substantial and similar for both contrast agents and scoring systems, but the agreement for LI-RADS categorization was lower.

• Abstract
• Full text
• PDF
• References

Open Access

oa

Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in HCC

Sheena Suthen,  Chun Jye Lim,  Phuong H. D. Nguyen,  Charles-Antoine Dutertre,  Hannah L. H. Lai,  Martin Wasser,  Camillus Chua,  Tony K. H. Lim,  Wei Qiang Leow,  Tracy Jiezhen Loh,  Wei Keat Wan,  Yin Huei Pang,  Gwyneth Soon,  Peng Chung Cheow,  Juinn Huar Kam,  Shridhar Iyer,  Alfred Kow,  Wai Leong Tam,  Timothy W. H. Shuen,  Han Chong Toh,  Yock Young Dan,  Glenn K. Bonney,  Chung Yip Chan,  Alexander Chung,  Brian K. P. Goh,  Weiwei Zhai,  Florent Ginhoux,  Pierce K. H. Chow,  Salvatore Albani,  Valerie Chew, 

• Pages: 1329-1344
• First Published: 20 February 2022

• Abstract
• Full text
• PDF
• References

LIVER PATHOBIOLOGY

no

Hepatic inflammation elicits production of proinflammatory netrin-1 through exclusive activation of translation

Romain Barnault,  Claire Verzeroli,  Carole Fournier,  Maud Michelet,  Anna Rita Redavid,  Ievgeniia Chicherova,  Marie-Laure Plissonnier,  Annie Adrait,  Olga Khomich,  Fleur Chapus,  Mathieu Richaud,  Maëva Hervieu,  Veronika Reiterer,  Federica Grazia Centonze,  Julie Lucifora,  Birke Bartosch,  Michel Rivoire,  Hesso Farhan,  Yohann Couté,  Valbona Mirakaj,  Thomas Decaens,  Patrick Mehlen,  Benjamin Gibert,  Fabien Zoulim,  Romain Parent, 

• Pages: 1345-1359
• First Published: 07 March 2022

• Abstract
• Full text
• PDF
• References

no

Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis

Lin Lei,  Alix Bruneau,  Haquima El Mourabit,  Justine Guégan,  Trine Folseraas,  Sara Lemoinne,  Tom Hemming Karlsen,  Bénédicte Hoareau,  Romain Morichon,  Ester Gonzalez-Sanchez,  Claire Goumard,  Vlad Ratziu,  Pierre Charbord,  Jérémie Gautheron,  Frank Tacke,  Thierry Jaffredo,  Axelle Cadoret,  Chantal Housset, 

• Pages: 1360-1375
• First Published: 12 March 2022

• Abstract
• Full text
• PDF
• References

Open Access

oa

Hepatic kinome atlas: An in-depth identification of kinase pathways in liver fibrosis of humans and rodents

Justin F. Creeden,  Zachary A. Kipp,  Mei Xu,  Robert M. Flight,  Hunter N. B. Moseley,  Genesee J. Martinez,  Wang-Hsin Lee,  Khaled Alganem,  Ali S. Imami,  Megan R. McMullen,  Sanjoy Roychowdhury,  Atta M. Nawabi,  Jennifer A. Hipp,  Samir Softic,  Steven A. Weinman,  Robert McCullumsmith,  Laura E. Nagy,  Terry D. Hinds Jr., 

• Pages: 1376-1388
• First Published: 21 March 2022

We compared human and mouse liver fibrosis with kinase activity measurements using the PamGene PamStation technology and bioinformatic analysis. The Insulin Receptor (INSR), DDR, DMPK, and PKA are the most active kinases among humans with cirrhosis and animal models of fibrosis.

• Abstract
• Full text
• PDF
• References

no

Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury

Li Chen,  Jun Dong,  Siyang Liao,  Siyou Wang,  Zhida Wu,  Meiling Zuo,  Bing Liu,  Chaojun Yan,  Yong Chen,  He He,  Qingtao Meng,  Zhiyin Song, 

• Pages: 1389-1408
• First Published: 21 March 2022

Chen et al. reveal that hepatocyte Sam50 reduction-induced cardiolipin externalization augments Bax/Bak oligomerlation and then facilates mtDNA release to aggrevate liver injury.

• Abstract
• Full text
• PDF
• References

LIVER FAILURE/CIRRHOSIS/PORTAL HYPERTENSION

no

Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease

Xinrong Zhang,  Grace Lai-Hung Wong,  Terry Cheuk-Fung Yip,  Johnny T. K. Cheung,  Yee-Kit Tse,  Vicki Wing-Ki Hui,  Huapeng Lin,  Jimmy Che-To Lai,  Henry Lik-Yuen Chan,  Alice Pik-Shan Kong,  Vincent Wai-Sun Wong, 

• Pages: 1409-1422
• First Published: 25 March 2022

Diabetes is an important risk factor for nonalcoholic fatty liver disease (NAFLD) and its severity. However, it is difficult to screen every diabetic patient for NAFLD because of the large number of patients. In a study of 7028 patients with NAFLD and type 2 diabetes from Hong Kong, we showed that the vast majority of patients developed liver-related complications after the age of 50 years. In contrast, liver-related events increased linearly with the duration of diabetes with no threshold effect. Our study suggests that screening for liver disease should be based on age instead of the duration of diabetes.

• Abstract
• Full text
• PDF
• References

no

Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?

Zobair M. Younossi,  James M. Paik,  Reem Al Shabeeb,  Pegah Golabi,  Issah Younossi,  Linda Henry, 

• Pages: 1423-1437
• First Published: 01 April 2022

MAFLD and NAFLD have similar clinical profiles and long-term outcomes. The increased liver-related mortality among MAFLD is primarily driven by alcoholic liver disease.

• Abstract
• Full text
• PDF
• References

PEDIATRICS

Open Access

oa

Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort

Coralie Amadou,  Oumarou Nabi,  Lawrence Serfaty,  Karine Lacombe,  Jérôme Boursier,  Philippe Mathurin,  Céline Ribet,  Victor de Ledinghen,  Marie Zins,  Marie-Aline Charles, 

• Pages: 1438-1451
• First Published: 26 April 2022

• Abstract
• Full text
• PDF
• References

STEATOHEPATITIS

no

Discovery of an insulin-induced gene binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting sterol regulatory element-binding protein–mediated lipogenesis

Shi-You Jiang,  Xinglin Yang,  Zimo Yang,  Jue-Wan Li,  Meng-Qiang Xu,  Yu-Xiu Qu,  Jing-Jie Tang,  Yun-Feng Li,  Liguo Wang,  Yi-Wen Shao,  Xin-Yuan Meng,  Huili Hu,  Bao-Liang Song,  Yu Rao,  Wei Qi, 

• Pages: 1466-1481
• First Published: 31 January 2022

• Abstract
• Full text
• PDF
• References

no

PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features

Eduardo Vilar-Gomez,  Carlos J. Pirola,  Silvia Sookoian,  Laura A. Wilson,  Tiebing Liang,  Naga Chalasani, 

• Pages: 1482-1494
• First Published: 29 March 2022

Half of the total effect of PNPLA3 rs738409 on fibrosis severity could be explained by a direct pathway without the mediation of other histology factors. The other half of the total effect of PNPLA3 rs738409 on fibrosis severity seems to be mediated primarily through portal inflammation.

• Abstract
• Full text
• PDF
• References

Open Access

oa

Risk of cardiovascular disease and loss in life expectancy in NAFLD

Ying Shang,  Patrik Nasr,  Linnea Widman,  Hannes Hagström, 

• Pages: 1495-1505
• First Published: 10 April 2022

• Abstract
• Full text
• PDF
• References

VIRAL HEPATITIS

Open Access

oa

Neutralization and receptor use of infectious culture–derived rat hepacivirus as a model for HCV

Raphael Wolfisberg,  Caroline E. Thorselius,  Eduardo Salinas,  Elizabeth Elrod,  Sheetal Trivedi,  Louise Nielsen,  Ulrik Fahnøe,  Amit Kapoor,  Arash Grakoui,  Charles M. Rice,  Jens Bukh,  Kenn Holmbeck,  Troels K. H. Scheel, 

• Pages: 1506-1519
• First Published: 21 April 2022

• Abstract
• Full text
• PDF
• References

• Pages: 1520-1530
• First Published: 28 March 2022

1. Circulating HBV RNA, which is primarily composed of full-length, spliced, and 3’ truncated pregenomic RNA, circulates in the blood of patients with chronic HBV infection predominantly in the form of virus-like particles, including enveloped virions and naked capsids (capsid-antibody complexes in patients’ sera).
2. HBV RNA–containing virions are secreted through the multivesicular body pathway, as are HBV DNA-virions, while the secretion pathway of HBV capsids remains elusive. HBV RNA–containing virions collected under HBV polymerase inhibitor treatment fail to establish de novo infection, but the infectivity of naive RNA virions remains to be investigated.
3. The quantitation levels of circulating HBV RNA and their performances on predicting treatment outcomes are largely methodology-dependent, calling for the standardization of serum HBV RNA detection assay.
4. The area of clinical interest in circulating HBV RNA is predicting off-treatment responses and HCC development in patients treated with nucleos(t)ide analogues.

• Pages: 1531-1549
• First Published: 30 April 2022

• Page: 1550
• First Published: 14 September 2022

• Page: 1551
• First Published: 15 September 2022

• Pages: 1552-1553
• First Published: 30 August 2022

• Page: 1554
• First Published: 08 September 2022

• Pages: E94-E95
• First Published: 16 April 2022

• Page: E96
• First Published: 19 April 2022

• Page: E97
• First Published: 17 April 2022

• Pages: E98-E99
• First Published: 18 April 2022

• Page: E100
• First Published: 09 May 2022

• Page: E101
• First Published: 09 May 2022

• Pages: E102-E103
• First Published: 09 May 2022

• Pages: E104-E105
• First Published: 01 May 2022

• Pages: E106-E107
• First Published: 26 June 2022

• Pages: E108-E109
• First Published: 05 July 2022

• Pages: E110-E111
• First Published: 01 July 2022

• Pages: E112-E113
• First Published: 01 July 2022

• Pages: E114-E115
• First Published: 01 July 2022

• First Published: 19 October 2022

• First Published: 19 October 2022